253 related articles for article (PubMed ID: 17909310)
21. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
22. [Use of iumeks in the combined therapy of parkinsonism patients ].
Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
[No Abstract] [Full Text] [Related]
23. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection for Parkinson's disease: prospects and promises.
Olanow CW; Schapira AH; Agid Y
Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
[No Abstract] [Full Text] [Related]
25. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
26. [Monoamine oxidase inhibitors: prospects for the use in clinical practice].
Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260
[No Abstract] [Full Text] [Related]
27. Rasagiline.
Schapira A; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
[No Abstract] [Full Text] [Related]
28. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
Lew MF
Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
[TBL] [Abstract][Full Text] [Related]
29. The fabulous neuroprotection of selegiline: memoir and prospectus.
Landau WM
J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
[No Abstract] [Full Text] [Related]
30. Monoamine oxidase inhibitors and their pharmacological significance.
Sandler M
Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
Roesler R; Quevedo J; Walz R; Bianchin M
Neurology; 1999 Jun; 52(9):1920-1. PubMed ID: 10371554
[No Abstract] [Full Text] [Related]
33. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
Di Rocco A
Neurology; 1999 Jun; 52(9):1920; author reply 1920-1. PubMed ID: 10371553
[No Abstract] [Full Text] [Related]
34. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
[TBL] [Abstract][Full Text] [Related]
35. Monoamine oxidase inhibitors and cardiac anesthesia revisited.
Noorily SH; Hantler CB; Sako EY
South Med J; 1997 Aug; 90(8):836-8. PubMed ID: 9258314
[TBL] [Abstract][Full Text] [Related]
36. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
37. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?
Rowland MJ; Bransome ED; Hendry LB
J Clin Pharmacol; 1994 Jan; 34(1):80-5. PubMed ID: 8132855
[TBL] [Abstract][Full Text] [Related]
38. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
39. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
Myllylä VV; Sotaniemi KA; Aasly J; Sjaastad O; Rinne U; McIntyre T; Cremer G
Adv Neurol; 1993; 60():676-80. PubMed ID: 8420209
[No Abstract] [Full Text] [Related]
40. [Monoamine oxidase inhibitors].
Naoi M; Nagatsu T
Nihon Rinsho; 1991 Sep; 49(9):2040-5. PubMed ID: 1960872
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
